Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Nippon Express has provided a pharmaceutical distribution platform with strict temperature control in two ranges -- 2 C to 8 C
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
New Director supports NASDAQ rule on diversity
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Subscribe To Our Newsletter & Stay Updated
